Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH, Humerickhouse RA, Seymour JF. Roberts AW, et al. Among authors: sweetenham jw. Br J Haematol. 2015 Sep;170(5):669-78. doi: 10.1111/bjh.13487. Epub 2015 May 5. Br J Haematol. 2015. PMID: 25942994 Free PMC article. Clinical Trial.
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. Press OW, et al. Among authors: sweetenham jw. J Clin Oncol. 2016 Jun 10;34(17):2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069074 Free PMC article. Clinical Trial.
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, Pettengell R, Johnson PW, Bessell E, Hancock B, Summers K, Hughes J, Rohatiner AZ, Lister TA. Foran JM, et al. Among authors: sweetenham jw. Br J Haematol. 2000 Apr;109(1):81-8. doi: 10.1046/j.1365-2141.2000.01965.x. Br J Haematol. 2000. PMID: 10848785 Free article. Clinical Trial.
Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
Nolan L, Lorigan P, Chilton S, Newman J, Else R, Smith P, Linch D, Sweetenham JW, Johnson PW. Nolan L, et al. Among authors: sweetenham jw. Br J Haematol. 2007 Jun;137(5):436-42. doi: 10.1111/j.1365-2141.2007.06587.x. Epub 2007 Apr 13. Br J Haematol. 2007. PMID: 17433027 Free article. Clinical Trial.
The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.
Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio M, Pohlman B, Tench S, Sobecks R, Andresen S, Copelan E, Sweetenham J. Hill BT, et al. Br J Haematol. 2011 Mar;152(5):561-9. doi: 10.1111/j.1365-2141.2010.08549.x. Epub 2011 Jan 12. Br J Haematol. 2011. PMID: 21223255 Free article.
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Ramsey SD, et al. Among authors: sweetenham jw. Br J Haematol. 2016 Dec;175(5):860-867. doi: 10.1111/bjh.14316. Epub 2016 Sep 21. Br J Haematol. 2016. PMID: 27649689 Free PMC article. Clinical Trial.
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. Wagner-Johnston ND, et al. Leuk Lymphoma. 2015;56(10):2863-9. doi: 10.3109/10428194.2015.1017821. Epub 2015 Mar 29. Leuk Lymphoma. 2015. PMID: 25707288 Clinical Trial.
149 results